Küçük hücreli olmayan akciğer kanserinde mitomisin, ifosfamid ve sisplatin içeren kemoterapi rejiminin etkinliğinin araştırılması

Küçük hücreli olmayan akciğer kanseri (KHOAK) tedavisinde tek ajan olarak en etkili ilaçlar olan mitomisin, ifosfamid ve sisplatinin etkinliğinin saptanması amacıyla 60 KHOAK olgusunda bu ilaçların kombinasyonu uygulanmıştır. Toplam yanıt oranı %36.5 olarak bulunmuştur. Bir yıllık sağkalım yanıt gözlenenlerde %61.5, yanıtsız olgularda %31, progresif grupta %20.5 ve tüm grupta %31.5 olarak saptanmıştır.

Mitomycin, ifosfamide and cisplatin in nonsmall cell lung cancer

In an effort to confirm the efficiacy of mitomycine, ifosfamide and cisplatin, 60 evaluable patients with nonsmall cell lung cancer were treated with combination of these drugs. The overall response rate was 36.5%. The 1-year survival of responders was 61.5%, for stationary group was 31%, for progressive group was 20.5% and for the whole group 31.5%.

PDF

___

1. Veeder M, Jett JR, Su JO, et al. A phase III trial of mitomycin C alone versus mitomycin C,vinbtastin, and sisplatin for metastatic squamous cell lung carcinoma. Cancer 1992; 70: 2281-7.
2. Wagner H. Rationat integration of radiation and chemotherapy in patient with unresectabte stage III A or III B NSCLC. Chest 1993; 103: 35-42.
3. Haskell CM. Drugs used in cancer chemotherapy. Cancer tratment. In: Haskell CM (ed). 3rd ed. Philadelphia:W Saunders Company 1990: 44-101.
4. Drings P. European experience with ifosfamide in nonsmall cell lung cancer. Seminars in Oncology 1989; 16: 22-30.
5. Giron CG, Ordonez A, Jalon I, et al. Combination chemotherapy with ifosfamide, mitomycin, and cisplatin in advanced nonsmall cell lung cancer. Cancer Treat Rep 1987; 71: 851-3.
6. Paccagnella A, Favaretto A, Brandes A, et al. Cisplatin, etoposide, and ifosfamide in nonsmall cell lung carcinoma. Cancer 1990; 65: 2631-4.
7. Rosell R, Esteve A, Moreno I, et al. A randomized study of two vindesin plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patient with advanced nonsmall cell lung cancer. Cancer 1990; 65: 1692-9.
8. Gurney H, Sydney E, Podwell D, et al. Ifosfamide and mitomycine in combination for the treatment of patients with progressive advanced nonsmall cell lung cancer. Eur J Cancer 1991; 27; 565-8.
9. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced nonsmall cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633-41.
10. Ganz AP, Figlin RA, Haskell CM, et al. Supportive care versus supportive care and combination chemotherapy in metastatic nonsmall cell lung cancer. Cancer 1989; 63: 1271-8.
11. Cullen MH, Joshi R, Chetiyawardana AD, et al. Mitomycin, ifosfamide, and cisplatin in nonsmall cell lung cancer; treatment good enough to compare. Br J Cancer 1988;58:359-61.
12. Currie DC, Miles DW, Drake JS, et al. Mitomycine, ifosfamide, and cisplatin in nonsmall cell lung cancer. Cancer Chemother Pharmacol 1990; 25:380-1.
13. Cullen MH. Mitomycin, ifosfamide and cisplatin in nonsmall cell lung cancer. Oncology 1993; 50: 31-4.
14. Rosell R, Maestre J, Font A, et al. A randomized trial of mitomycine/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage III A nonsmall cell lung cancer. Seminars in Oncology 1994; 21:28-33.
15. Greco FA. The rational for chemotherapy for advanced nonsmall cell lung cancer. Royal society of medicine services international congress and symposium series, no 150,-ln: Gralla RJ, Einhorn LH (ed). Nashville, Royal Society of Medicine Services 1989:95-100.
16. Joss RA, Barki K, Dalquen P, et al. Combination chemotherapy with mitomycin, vindesin, and cisplatin for nonsmall cell lung cancer. Cancer 1990; 65: 2426-34.
17. Minna JD, Pass H. Cancer of the lung. In: Devita VT, Hellman S (eds). Cancer: Principles and practice of oncology. 3rd ed. Philadelphia: JB Lippincott Company 1989:591-687.
18. Crino L, Corgna E, Porrozzi S, A better therapeutic profile for the combination of mitomycin-C, ifosfamide and sisplatin (MIC) in advanced nonsmallcell lung cancer: A useful dose-schedule modification. Ann Oncol 1997; 8: 709-11.
19. Palmer AJ, Brandt A. The cost-effectiveness of four sisplatin-containing chemotherapy regimens in the treatment of stages III B and IV nonsmall cell lung cancer: An Italian perspective. Monaldi Arch Chest Dis 1996; 51: 279-88.
20. Rosell R, Font A, Pifarre A. The role of Induction (neoad-juvant) chemotherapy in stage IIIA NSCLC. Chest 1996;109(5 SuppI): 102-6.
21. Urban T, Bedin A, Baud M. Efficacy and toxtcity of mitomycin, ifosfamide, and sisplatin (MIP) in patients with inoperable nonsmall cell lung cancer. Lung Cancer 1996; 14: 109-17.
22. Milroy R, Macbeth F. Neoadjuvant chemotherapy in stage llla nonsmall cell lung cancer. Thorax 1995; 50 (Suppl); 25-30.